Sensus Healthcare, Inc. (NASDAQ:SRTS) Short Interest Update

Sensus Healthcare, Inc. (NASDAQ:SRTS) was the recipient of a large drop in short interest in the month of March. As of March 13th, there was short interest totaling 394,950 shares, a drop of 18.3% from the February 26th total of 483,655 shares. Based on an average trading volume of 102,973 shares, the short-interest ratio is currently 3.8 days. Approximately 2.6% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

SRTS has been the topic of a number of recent analyst reports. Wall Street Zen downgraded Sensus Healthcare from a “hold” rating to a “sell” rating in a research report on Saturday, February 14th. Maxim Group reduced their target price on Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. Alliance Global Partners started coverage on shares of Sensus Healthcare in a research note on Friday, March 6th. They issued a “buy” rating and a $7.50 price target on the stock. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Sensus Healthcare in a report on Thursday, January 22nd. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $6.88.

Institutional Trading of Sensus Healthcare

Several large investors have recently bought and sold shares of SRTS. Opes Wealth Management LLC acquired a new stake in Sensus Healthcare in the 3rd quarter valued at about $50,000. XTX Topco Ltd acquired a new position in shares of Sensus Healthcare during the 4th quarter worth approximately $77,000. Jane Street Group LLC purchased a new stake in shares of Sensus Healthcare in the fourth quarter valued at approximately $79,000. Mindset Wealth Management LLC increased its holdings in shares of Sensus Healthcare by 28.1% in the third quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock valued at $157,000 after purchasing an additional 11,000 shares during the last quarter. Finally, Ingalls & Snyder LLC acquired a new stake in shares of Sensus Healthcare in the fourth quarter valued at approximately $219,000. Hedge funds and other institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Stock Down 1.8%

Shares of NASDAQ SRTS traded down $0.07 during midday trading on Monday, hitting $3.85. The stock had a trading volume of 11,308 shares, compared to its average volume of 93,898. The stock has a 50 day simple moving average of $4.41 and a 200-day simple moving average of $3.98. The company has a market capitalization of $63.40 million, a PE ratio of -8.19 and a beta of 1.22. Sensus Healthcare has a 1 year low of $3.03 and a 1 year high of $5.92.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings data on Thursday, February 12th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.10). Sensus Healthcare had a negative net margin of 28.09% and a negative return on equity of 15.11%. The firm had revenue of $4.94 million during the quarter, compared to analysts’ expectations of $8.35 million. As a group, analysts expect that Sensus Healthcare will post 0.32 earnings per share for the current fiscal year.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.